MedWatch

Ambu's new duodenoscope reaches over 98 percent success rate

Clinical testing of Ambu's improved duodenoscope, the Ascope Duodeno 1.5, continues to yield promising results, the medtech company reports on Monday.

Photo: PR / Ambu

Ambu has once again obtained positive results from clinical testing of its improved single-use duodenoscope, the Ascope Duodeno 1.5, it reports in a press release.

In connection with Ambu's results from the finanical year 2020/2021, which were announced in early November, the medtech company announced that 29 people had tested the Ascope Duodeno 1.5, with a success rate of 100 percent.

Read the whole article

Get 14 days free access.
No credit card required.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

"Real world" patient data documents the long-term effects of ALK vaccines

In the largest study ever of its kind, patient data from the "real world" documents the long-term effects of up to nine years of ALK vaccines. Up until now, it has not been possible to demonstrate these in ordinary clinical studies where the follow-up period is shorter, and the new knowledge could be a turning point in ALK's dialog about prices and subsidies with authorities and payers. 

Further reading

Related articles

Latest news

See all jobs